BIVI - BioVie Forward P/S Multiple

Brandmark of BioVie Inc (BIVI)

BioVie Inc. (BIVI) management is focusing on dementia and liver pathology therapies, foregoing dividend payments to fund clinical trial development. The GURU.Markets terminal displays a forward P/S ratio chart, where the current reading is , confirming market confidence. The production of hepatoprotectors has been outsourced to external CDMO partners to optimize processes, while innovative drugs target inflammation and brain insulin resistance.

BIVI BioVie Pharma: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for BioVie Inc.

- current price and projected stock value:
Stock Price BioVie|BIVI - Price Target Chart
- market capitalization statistics:
Market Capitalization BIVI|BIVI - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share BioVie|BIVI - Total Stockholders' Equity|Market Cap to Net Assets Ratio biovieinc.com|BIVI - Aggregate Company Assets
- company liabilities and liquidity data:
Total Debt to Capital BioVie Inc.|BIVI - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital BioVie|BIVI - Company Cumulative Debt|Debt to Book Value BIVI|BIVI - Company Long-Term Loans and Borrowings|Company Short-Term Debts BioVie|Quick Liquidity biovieinc.com
- business earnings and investment ratios data:
BIVI - Company Profit|Projected Future Earnings BioVie Inc.|BIVI - Price to Earnings Ratio|Projected Price to Earnings BioVie|BIVI - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple BIVI|BIVI - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) BioVie|BIVI - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months biovieinc.com|BIVI - Earnings per share growth in current year|Earnings growth forecast for next year BioVie Inc.
- revenue and sales details:
BIVI - Company Gross Revenue|Company Projected Revenue BioVie|BIVI - Price-to-Sales Ratio|Forward P/S Multiple BIVI
Initial company analysis:BioVie Pharma (BIVI)
Product sample of biovieinc.com

Forward P/S assesses market capitalization relative to expected annual sales, allowing an investor to determine the extent of overpayment for future cash flows via the projected P/S parameter. For BioVie Inc. (BIVI), this metric reflects the speculative value of potential drug approvals rather than a market cycle, where the coefficient's dynamics depend directly on the success of clinical trials and the availability of venture capital.

Key competitors

Forward P/S Multiple ARWR (Arrowhead Pharmaceuticals, Inc.)|Mirum Pharmaceuticals, Inc. - Price-to-Projected Revenue Ratio|Dynavax Pharma - Forward P/S Multiple|Market Cap to Expected Sales Ratio Tekmira Pharmaceuticals ABUS|Inventiva S.A. (IVA) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio gyretx.com (GYRE)|Forward Price-to-Revenue Multiple ASMB|Price-to-Projected Revenue Ratio GALT|Forward P/S Multiple GNFT|Market Cap to Expected Sales Ratio durect.com|Forward P/S Multiple ALGS (Aligos Therapeutics, Inc.)|Galmed Pharmaceuticals Ltd (GLMD) - Market Cap to Future Revenue Ratio|NDRA: Forward Price-to-Revenue Multiple|Forward Price to Sales HEPA (Hepion Pharmaceuticals)